Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 14/2004

01-12-2004 | Original Research Article

Current Use of Selective Serotonin Reuptake Inhibitors and Risk of Acute Myocardial Infarction

Authors: Raymond G. Schlienger, Lorenz M. Fischer, Hershel Jick, Dr Christoph R. Meier

Published in: Drug Safety | Issue 14/2004

Login to get access

Abstract

Background: It has been suggested that increased platelet activation increases the risk of acute myocardial infarction (AMI) in patients with depression. Selective serotonin reuptake inhibitors (SSRIs) may attenuate platelet activation by serotonin depletion in platelets. Observational studies have shown discrepant results of AMI risk associated with the use of SSRIs.
Objective: The aim of this study was to evaluate the association of exposure to different groups of antidepressants, including SSRIs, and the risk of AMI. The study also assessed in more detail the influence of timing of the exposure to antidepressants in a general adult population (<90 years of age), with or without diagnosed risk factors for AMI.
Study design/methods: We conducted a population-based case-control analysis on the UK General Practice Research Database (GPRD). The study included 8688 patients (<90 years of age), with a first-time AMI between 1995 and 2001, and 33 923 controls, who were matched by age, sex, calendar time, and general practice. Conditional logistic regression was used to estimate odds ratios (ORs).
Results: Current use of an antidepressant was defined as a supply of the last prescription for an antidepressant that lasted up to the index date or beyond. Recent past use was defined as a supply of the last prescription for an antidepressant that ended 1–29 days before the index date. SSRIs investigated were citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline and venlafaxine. Non-SSRIs investigated were amitriptyline, clomipramine, dosulepin, doxepin, imipramine, lofepramine, nefazodone, trazodone and trimipramine. Other antidepressants included were amoxapine, desipramine, lithium, maprotiline, mianserin, moclobemide, nortriptyline and protriptyline. Adjusted ORs (with 95% CI) for the current use of SSRIs, non-SSRIs, or other antidepressants, compared with non-use of antidepressants, were 0.63 (95% CI 0.43, 0.91; p = 0.02), 0.92 (95% CI 0.77, 1.09; p = 0.32) and 0.59 (95% CI 0.29, 1.20; p = 0.14), respectively. The adjusted OR of recent past use of SSRIs compared with non-use of SSRIs was 1.42 (95% CI 1.02, 1.97; p = 0.04).
Conclusion: The present analysis provides further evidence that the current use of SSRIs is associated with a slightly decreased risk for AMI.
Literature
1.
Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58(3): 221–7PubMedCrossRef
2.
Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men. Arch Intern Med 1998; 158(13): 1422–6PubMedCrossRef
3.
Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93(11): 1976–80PubMedCrossRef
4.
Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996; 94(12): 3123–9PubMedCrossRef
5.
Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91(4): 999–1005PubMedCrossRef
6.
Stewart RA, North FM, West TM, et al. Depression and cardiovascular morbidity and mortality: cause or consequence? Eur Heart J 2003; 24(22): 2027–37PubMedCrossRef
7.
Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55(7): 580–92PubMedCrossRef
8.
Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140Suppl. 4: 57–62PubMedCrossRef
9.
Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psychosom Med 1991; 53(6): 643–68PubMed
10.
Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153(10): 1313–7PubMed
11.
Lederbogen F, Gilles M, Maras A, et al. Increased platelet aggregability in major depression? Psychiatry Res 2001; 102(3): 255–61PubMedCrossRef
12.
Zellweger MJ, Osterwalder RH, Langewitz W, et al. Coronary artery disease and depression. Eur Heart J 2004; 25(13): 3–9PubMedCrossRef
13.
Celada P, Dolera M, Alvarez E, et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992; 25(4): 243–50PubMedCrossRef
14.
Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68(4): 435–42PubMedCrossRef
15.
Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000; 57(9): 875–82PubMedCrossRef
16.
Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43(5): 453–62PubMedCrossRef
17.
Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91(1): 119–28PubMed
18.
Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs 2003; 3(3): 149–62PubMedCrossRef
19.
Nair GV, Gurbel PA, O’Connor CM, et al. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol 1999; 84(3): 321–3PubMedCrossRef
20.
Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108(1): 2–8PubMedCrossRef
21.
Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104(16): 1894–8PubMedCrossRef
22.
Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108(1): 32–6PubMedCrossRef
23.
Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52(2): 179–84PubMedCrossRef
24.
25.
Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45(5): 419–25PubMedCrossRef
26.
27.
Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 1991; 302(6779): 766–8PubMedCrossRef
28.
Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1(6): 347–9CrossRef
29.
Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23(5): 686–9PubMedCrossRef
30.
Meier CR, Jick SS, Derby LE, et al. Acute respiratory tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351(9114): 1467–71PubMedCrossRef
31.
Meier CR, Derby LE, Jick SS, et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281(5): 427–31PubMedCrossRef
32.
Schlienger RG, Jick H, Meier CR. Use of nonsteroidal antiinflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002; 54(3): 327–32PubMedCrossRef
33.
Jick H, Vasilakis C, Derby LE. Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension. Epidemiology 1997; 8(4): 446–8PubMedCrossRef
34.
Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288(14): 701–9PubMedCrossRef
35.
Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37(5): 1297–302PubMedCrossRef
36.
Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000; 25(3): 255–61PubMed
37.
38.
Ditto KE. SSRI discontinuation syndrome: awareness as an approach to prevention. Postgrad Med 2003; 114(2): 79–84PubMedCrossRef
39.
Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3 (1): 13–37CrossRef
40.
Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997; 17(6): 390–406PubMedCrossRef
41.
Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry [letter] 1992; 149(3): 412
42.
Berg C, Couturier F, Grass F, et al. Saignements sous inhibiteurs de la recapture de la sérotonine: à propos d’un cas clinique. Therapie 2001; 56(1): 65–7PubMedCrossRef
43.
Cooper TA, Valcour VG, Gibbons RB, et al. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998; 104(2): 197–8PubMedCrossRef
44.
Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10(1): 35–8PubMedCrossRef
45.
46.
de Abajo F, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50(1): 43–7PubMedCrossRef
47.
Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163(1): 59–64PubMedCrossRef
48.
Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57(2): 167–76PubMedCrossRef
Metadata
Title
Current Use of Selective Serotonin Reuptake Inhibitors and Risk of Acute Myocardial Infarction
Authors
Raymond G. Schlienger
Lorenz M. Fischer
Hershel Jick
Dr Christoph R. Meier
Publication date
01-12-2004
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 14/2004
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200427140-00006

Other articles of this Issue 14/2004

Drug Safety 14/2004 Go to the issue

Review Article

Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents

Review Article

Fab Antibody Fragments

Review Article

Benefit-Risk Assessment of Ropivacaine in the Management of Postoperative Pain

Current Opinion

Can We Ensure the Safe Use of Known Human Teratogens?

Review Article

Overview of the Tolerability of Gefitinib (IRESSA™) Monotherapy